Global Contrast-Enhanced Mammography Supply, Demand and Key Producers, 2026-2032
The global Contrast-Enhanced Mammography market size is expected to reach $ 465 million by 2032, rising at a market growth of 5.9% CAGR during the forecast period (2026-2032).
Contrast-Enhanced Mammography (CEM) is a breast imaging technique that builds on standard digital mammography by administering intravenous iodinated contrast and acquiring dual-energy images (low- and high-energy) to reconstruct enhancement/“iodine-only” images. It provides both anatomic detail (similar to conventional mammography) and functional information related to vascularity and permeability, making contrast uptake more conspicuous in many cancers. CEM is particularly relevant for dense breasts, problem-solving in equivocal cases, scenarios where breast MRI is contraindicated or less accessible, and selected pathways such as preoperative evaluation and treatment follow-up. Its clinical and operational value depends on standardized contrast administration and timing, a robust dual-energy imaging chain, and workflow-integrated reading and reporting—so performance gains translate into reproducible, scalable practice. In 2025, global Contrast-Enhanced Mammography production reached approximately 1506 unit and price is about 200 K USD/Unit.The average gross profit margin of this product is 50%.
Sustained demand for earlier detection and higher-throughput breast imaging is pushing radiology departments to adopt solutions that improve sensitivity without disrupting established mammography infrastructure. CEM supports “bringing enhancement capability onto the mammography platform,” leveraging familiar equipment ecosystems and scalable protocols. For providers, CEM can serve as a complementary—or in selected indications, alternative—pathway to breast MRI, helping shorten diagnostic timelines, improve access, and align enhancement imaging with existing mammography workflows, QC frameworks, and staffing models. CEM combines contrast administration, radiation-based imaging, and workflow governance, meaning implementation barriers extend beyond hardware to patient screening (e.g., contrast reactions and renal considerations), timing control, emergency readiness, and cross-team coordination. Clinically, positioning CEM alongside MRI, ultrasound, and tomosynthesis requires clear boundaries and standardized interpretation training to avoid excessive false positives or unnecessary follow-ups. Without strong evidence loops and disciplined QC, hospitals may face uncertainty in defining CEM’s role and sustaining consistent utilization. Demand is shifting from single-test accuracy to pathway-level efficiency—linking CEM with tomosynthesis, targeted ultrasound, biopsy workflows, and preoperative decision-making to enable faster, more streamlined “test-to-decision” cycles. In practice, CEM is often expected to deliver the greatest incremental value in dense breasts, lesion stratification, and MRI-limited populations, with gradual expansion into higher-frequency follow-up and recurrence surveillance scenarios. Meanwhile, radiology leaders increasingly prioritize structured reporting, AI assistance, and cross-site consistency to operationalize quality at scale. The upstream value chain is anchored by “contrast agent & injection systems + dual-energy mammography platform + software/QA components.” Iodinated contrast media and injectors/consumables define administration stability and safety boundaries; dual-energy detectors, x-ray tubes, generators, and compression mechanics drive image consistency and reproducibility; and reconstruction/post-processing software (low-energy images, iodine/enhancement images, artifact suppression, dose management) determines readability and workflow efficiency. Competitive differentiation concentrates on balancing low dose with high contrast, user-friendly reconstruction and reading software, integration with RIS/PACS and structured reporting, and lifecycle QA and service delivery capabilities.
This report studies the global Contrast-Enhanced Mammography production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Contrast-Enhanced Mammography and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Contrast-Enhanced Mammography that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Contrast-Enhanced Mammography total production and demand, 2021-2032, (Units)
Global Contrast-Enhanced Mammography total production value, 2021-2032, (USD Million)
Global Contrast-Enhanced Mammography production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Units), (based on production site)
Global Contrast-Enhanced Mammography consumption by region & country, CAGR, 2021-2032 & (Units)
U.S. VS China: Contrast-Enhanced Mammography domestic production, consumption, key domestic manufacturers and share
Global Contrast-Enhanced Mammography production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Units)
Global Contrast-Enhanced Mammography production by Type, production, value, CAGR, 2021-2032, (USD Million) & (Units)
Global Contrast-Enhanced Mammography production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Units)
This report profiles key players in the global Contrast-Enhanced Mammography market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hologic, GE Healthcare, Siemens, FUJIFILM, Philips Healthcare, Canon Medical, IMS Giotto, Planmed, Carestream Health, Metaltronica, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Contrast-Enhanced Mammography market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Units) and average price (K USD/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Contrast-Enhanced Mammography Market, By Region:
1. How big is the global Contrast-Enhanced Mammography market?
2. What is the demand of the global Contrast-Enhanced Mammography market?
3. What is the year over year growth of the global Contrast-Enhanced Mammography market?
4. What is the production and production value of the global Contrast-Enhanced Mammography market?
5. Who are the key producers in the global Contrast-Enhanced Mammography market?
6. What are the growth factors driving the market demand?
Contrast-Enhanced Mammography (CEM) is a breast imaging technique that builds on standard digital mammography by administering intravenous iodinated contrast and acquiring dual-energy images (low- and high-energy) to reconstruct enhancement/“iodine-only” images. It provides both anatomic detail (similar to conventional mammography) and functional information related to vascularity and permeability, making contrast uptake more conspicuous in many cancers. CEM is particularly relevant for dense breasts, problem-solving in equivocal cases, scenarios where breast MRI is contraindicated or less accessible, and selected pathways such as preoperative evaluation and treatment follow-up. Its clinical and operational value depends on standardized contrast administration and timing, a robust dual-energy imaging chain, and workflow-integrated reading and reporting—so performance gains translate into reproducible, scalable practice. In 2025, global Contrast-Enhanced Mammography production reached approximately 1506 unit and price is about 200 K USD/Unit.The average gross profit margin of this product is 50%.
Sustained demand for earlier detection and higher-throughput breast imaging is pushing radiology departments to adopt solutions that improve sensitivity without disrupting established mammography infrastructure. CEM supports “bringing enhancement capability onto the mammography platform,” leveraging familiar equipment ecosystems and scalable protocols. For providers, CEM can serve as a complementary—or in selected indications, alternative—pathway to breast MRI, helping shorten diagnostic timelines, improve access, and align enhancement imaging with existing mammography workflows, QC frameworks, and staffing models. CEM combines contrast administration, radiation-based imaging, and workflow governance, meaning implementation barriers extend beyond hardware to patient screening (e.g., contrast reactions and renal considerations), timing control, emergency readiness, and cross-team coordination. Clinically, positioning CEM alongside MRI, ultrasound, and tomosynthesis requires clear boundaries and standardized interpretation training to avoid excessive false positives or unnecessary follow-ups. Without strong evidence loops and disciplined QC, hospitals may face uncertainty in defining CEM’s role and sustaining consistent utilization. Demand is shifting from single-test accuracy to pathway-level efficiency—linking CEM with tomosynthesis, targeted ultrasound, biopsy workflows, and preoperative decision-making to enable faster, more streamlined “test-to-decision” cycles. In practice, CEM is often expected to deliver the greatest incremental value in dense breasts, lesion stratification, and MRI-limited populations, with gradual expansion into higher-frequency follow-up and recurrence surveillance scenarios. Meanwhile, radiology leaders increasingly prioritize structured reporting, AI assistance, and cross-site consistency to operationalize quality at scale. The upstream value chain is anchored by “contrast agent & injection systems + dual-energy mammography platform + software/QA components.” Iodinated contrast media and injectors/consumables define administration stability and safety boundaries; dual-energy detectors, x-ray tubes, generators, and compression mechanics drive image consistency and reproducibility; and reconstruction/post-processing software (low-energy images, iodine/enhancement images, artifact suppression, dose management) determines readability and workflow efficiency. Competitive differentiation concentrates on balancing low dose with high contrast, user-friendly reconstruction and reading software, integration with RIS/PACS and structured reporting, and lifecycle QA and service delivery capabilities.
This report studies the global Contrast-Enhanced Mammography production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Contrast-Enhanced Mammography and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Contrast-Enhanced Mammography that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Contrast-Enhanced Mammography total production and demand, 2021-2032, (Units)
Global Contrast-Enhanced Mammography total production value, 2021-2032, (USD Million)
Global Contrast-Enhanced Mammography production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (Units), (based on production site)
Global Contrast-Enhanced Mammography consumption by region & country, CAGR, 2021-2032 & (Units)
U.S. VS China: Contrast-Enhanced Mammography domestic production, consumption, key domestic manufacturers and share
Global Contrast-Enhanced Mammography production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (Units)
Global Contrast-Enhanced Mammography production by Type, production, value, CAGR, 2021-2032, (USD Million) & (Units)
Global Contrast-Enhanced Mammography production by Application, production, value, CAGR, 2021-2032, (USD Million) & (Units)
This report profiles key players in the global Contrast-Enhanced Mammography market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Hologic, GE Healthcare, Siemens, FUJIFILM, Philips Healthcare, Canon Medical, IMS Giotto, Planmed, Carestream Health, Metaltronica, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Contrast-Enhanced Mammography market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (Units) and average price (K USD/Unit) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Contrast-Enhanced Mammography Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Dual-energy CEM
- Single-energy Enhanced
- Screening
- Diagnostic Workup
- Pre-op Staging
- Other
- Dedicated CEM Mammography
- Upgrade from Standard System
- Other
- Hospital
- Physical Examination Center
- Other
- Hologic
- GE Healthcare
- Siemens
- FUJIFILM
- Philips Healthcare
- Canon Medical
- IMS Giotto
- Planmed
- Carestream Health
- Metaltronica
- MEDI-FUTURE
- Wandong Medical
- ANKE
- Sino MDT
- Angell
- United Imaging Healthcare
- Alltech Healthcare
- Neusoft Healthcare
- SevenHealth
1. How big is the global Contrast-Enhanced Mammography market?
2. What is the demand of the global Contrast-Enhanced Mammography market?
3. What is the year over year growth of the global Contrast-Enhanced Mammography market?
4. What is the production and production value of the global Contrast-Enhanced Mammography market?
5. Who are the key producers in the global Contrast-Enhanced Mammography market?
6. What are the growth factors driving the market demand?
